Merck's earnings call highlighted strong Q1 performance, driven by KEYTRUDA and GARDASIL sales growth.  Management expressed confidence in the company's pipeline, especially with the recent FDA approval of WINREVAIR and advancements in several other therapeutic areas.  The updated guidance suggests continued momentum and reinforces a positive outlook for the next 2 weeks, with WINREVAIR launch likely to be a catalyst.

[1]
